13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001969764
Total reported value
$191.1M
$191.1M
38 檔
34.6%
During the Q1 2026 filing period, Propel Bio Management, LLC (CIK: 0001969764) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $191.1M across 38 reported positions.
In Q1 2026, Propel Bio Management, LLC displayed an active expansion posture, initiating 22 new positions and adding to 6 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PAGP | Plains Gp Holdings Lp-cl A | Stock-Energy | 19.02% | -2.86% | — | |
| 2 | ACHV | Achieve Life Sciences Inc | Stock-Other | 7.17% | +6.62% | — | |
| 3 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 5.90% | +0.06% | +13.54% | |
| 4 | DCTH | Delcath Systems Inc | Stock-Other | 5.77% | -0.03% | +123.42% | |
| 5 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 3.80% | +2.41% | — | |
| 6 | ABEO | Abeona Therapeutics Inc | Stock-Other | 3.79% | -0.61% | +60.08% | |
| 7 | VOR | Vor Biopharma Inc | Stock-Other | 3.52% | -3.52% | EXIT | |
| 8 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 3.52% | +0.60% | -3.34% | |
| 9 | MIST | Milestone Pharmaceuticals In | Stock-Other | 3.20% | +2.01% | — | |
| 10 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.61% | -0.59% | -14.86% | |
| 11 | CMPS | Compass Pathways PLC | Stock-Other | 2.60% | +1.64% | -13.89% | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.58% | -2.58% | EXIT | |
| 13 | IVA | Inventiva SA - Adr | Stock-Other | 2.52% | +0.01% | -27.53% | |
| 14 | SABS | Sab Biotherapeutics Inc | Stock-Other | 2.45% | -0.25% | +55.13% | |
| 15 | OBIO | Orchestra Biomed Holdings In | Stock-Other | 2.41% | -0.39% | — | |
| 16 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.26% | -0.50% | — | |
| 17 | OCS | Oculis Holding AG | Stock-Other | 2.07% | -2.07% | EXIT | |
| 18 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.03% | -0.19% | — | |
| 19 | UPB | Upstream Bio Inc | Stock-Other | 1.95% | -0.68% | — | |
| 20 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.86% | +1.28% | — | |
| 21 | EYPT | Eyepoint Inc | Stock-Other | 1.76% | -0.33% | — | |
| 22 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.67% | -1.67% | EXIT | |
| 23 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 1.66% | +0.24% | +343.47% | |
| 24 | VTLUSD | Immunic Inc | Stock-Other | 1.65% | -1.65% | EXIT | |
| 25 | CHRS | Coherus Oncology Inc | Stock-Other | 1.52% | -1.52% | EXIT | |
| 26 | OVID | Ovid Therapeutics Inc | Stock-Other | 1.28% | +0.29% | — | |
| 27 | PALI | Palisade Bio Inc | Stock-Other | 1.26% | +1.56% | — | |
| 28 | KLRS | Kalaris Therapeutics Inc | Stock-Other | 1.08% | -1.08% | EXIT | |
| 29 | QURE | uniQure N.V. | Stock-Other | 1.08% | -1.08% | EXIT | |
| 30 | LONA | Leonabio Inc | Stock-Other | 0.94% | -0.22% | — | |
| 31 | NUVB | Nuvation Bio Inc | Stock-Other | 0.89% | -0.89% | EXIT | |
| 32 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.82% | -0.14% | — | |
| 33 | EVMN | Evommune Inc | Stock-Other | 0.81% | -0.81% | EXIT | |
| 34 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.79% | -0.24% | — | |
| 35 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.78% | -0.78% | EXIT | |
| 36 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.60% | +2.94% | — | |
| 37 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 0.35% | -0.35% | EXIT | |
| 38 | MSLE | Satellos Bioscience Inc | Stock-Other | 0.04% | -0.04% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | +2% | +123.42% | Add |
| 2 | ZVRA | Zevra Therapeutics Inc | +1.2% | +343.47% | Add |
| 3 | KLRS | Kalaris Therapeutics Inc | +0.8% | +603.33% | Add |
| 4 | SABS | Sab Biotherapeutics Inc | +0.4% | +55.13% | Add |
| 5 | ABEO | Abeona Therapeutics Inc | +0.1% | +60.08% | Add |
| 6 | LONA | Leonabio Inc | 0% | — | Unchanged |
| 7 | OCS | Oculis Holding AG | -0.9% | -29.29% | Trim |
| 8 | CLDX | Celldex Therapeutics Inc | -1% | -14.86% | Trim |
| 9 | IVA | Inventiva SA - Adr | -1.5% | -27.53% | Trim |
| 10 | PAGP | Plains Gp Holdings Lp-cl A | -1.8% | — | Unchanged |
| 11 | KYTX | Kyverna Therapeutics Inc | -1.8% | -3.34% | Trim |
| 12 | CMPS | Compass Pathways PLC | -2.5% | -13.89% | Trim |
| 13 | MIST | Milestone Pharmaceuticals In | -3.9% | — | Unchanged |
| 14 | PHAT | Phathom Pharmaceuticals Inc | -4.6% | +13.54% | Add |
| 15 | VRDN | Viridian Therapeutics Inc | -4.9% | -25.61% | Trim |
| 16 | ACHV | Achieve Life Sciences Inc | -8.9% | — | Unchanged |
| 17 | CORT | Corcept Therapeutics Inc | — | NEW | New buy |
| 18 | VOR | Vor Biopharma Inc | — | NEW | New buy |
| 19 | OBIO | Orchestra Biomed Holdings In | — | NEW | New buy |
| 20 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 21 | NKTR | Nektar Therapeutics | — | EXIT | Sold out |
| 22 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 23 | UPB | Upstream Bio Inc | — | NEW | New buy |
| 24 | AQST | Aquestive Therapeutics Inc | — | NEW | New buy |
| 25 | EYPT | Eyepoint Inc | — | NEW | New buy |
| 26 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 27 | VTLUSD | Immunic Inc | — | NEW | New buy |
| 28 | CHRS | Coherus Oncology Inc | — | NEW | New buy |
| 29 | OVID | Ovid Therapeutics Inc | — | NEW | New buy |
| 30 | PALI | Palisade Bio Inc | — | NEW | New buy |
| 31 | QURE | uniQure N.V. | — | NEW | New buy |
| 32 | RGNX | Regenxbio Inc | — | EXIT | Sold out |
| 33 | NUVB | Nuvation Bio Inc | — | NEW | New buy |
| 34 | MAZE | Maze Therapeutics Inc | — | NEW | New buy |
| 35 | EVMN | Evommune Inc | — | NEW | New buy |
| 36 | CRVS | Corvus Pharmaceuticals Inc | — | NEW | New buy |
| 37 | ALDX | Aldeyra Therapeutics Inc | — | NEW | New buy |
| 38 | ARTV | Artiva Biotherapeutics Inc | — | NEW | New buy |
| 39 | LENZ | Lenz Therapeutics Inc | — | EXIT | Sold out |
| 40 | AARD | Aardvark Therapeutics Inc | — | EXIT | Sold out |
| 41 | ✓ | Connect Biopharma Hldgs LTD | — | NEW | New buy |
| 42 | MSLE | Satellos Bioscience Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Propel Bio Management, LLC reported a total U.S. public equity portfolio value of $191.1M across 38 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PAGP, ACHV, PHAT) accounted for 34.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
CORT
市值: $6.0M
Top Position Liquidated / Trimmed
NKTR
前期市值: $3.5M
During Q1 2026, Propel Bio Management, LLC's top holdings by market value included PAGP (19.0%)、ACHV (7.2%)、PHAT (5.9%). The largest single position, PAGP, represented 19.0% of total portfolio value.
In Q1 2026, Propel Bio Management, LLC made 38 total portfolio adjustments, initiating 22 new buys, adding to 6 positions, trimming 6 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.